KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $6.8 million.

  • Acadia Pharmaceuticals' Cash from Financing Activities rose 3416.04% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 million, marking a year-over-year increase of 183.08%. This contributed to the annual value of $6.8 million for FY2024, which is 72.76% down from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $6.8 million for FY2024, which was down 72.76% from $25.1 million recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year Cash from Financing Activities high stood at $81.0 million for FY2020, and its period low was $6.8 million during FY2024.
  • Its 3-year average for Cash from Financing Activities is $13.4 million, with a median of $8.2 million in 2022.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Cash from Financing Activities slumped by 78.22% in 2020, and later soared by 206.49% in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $81.0 million in 2020, then tumbled by 77.58% to $18.2 million in 2021, then crashed by 54.86% to $8.2 million in 2022, then spiked by 206.49% to $25.1 million in 2023, then tumbled by 72.76% to $6.8 million in 2024.